AI Insight
The OPTIMA-AF trial compared 1-month versus 12-month dual antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention with intravascular imaging guidance. The study found that 1-month therapy followed by direct oral anticoagulant monotherapy was non-inferior for preventing death or thromboembolic events and significantly reduced major or clinically relevant non-major bleeding at 12 months. However, the researchers noted that efficacy results should be interpreted cautiously due to lower-than-expected event rates.
Why it matters
This trial suggests that patients with atrial fibrillation undergoing coronary stenting may safely receive shorter duration dual therapy, reducing bleeding risk without compromising protection against clots. The findings could influence clinical guidelines and reduce complications in a large patient population requiring both anticoagulation for atrial fibrillation and antiplatelet therapy after stent placement.
Understand the Science
Among patients with atrial fibrillation and predominantly chronic coronary syndrome undergoing PCI with intravascular imaging guidance, 1-month dual antithrombotic therapy followed by DOAC monotherapy was non-inferior to 12-month therapy for death or thromboembolic events and reduced major or clinically relevant non-major bleeding at 12 months, suggesting an overall favourable net clinical profile. Efficacy findings should be interpreted with appropriate caution in light of the lower-than-anticipated event rates and fixed absolute non-inferiority margin.